Skip to content
Bookmark Icon
Print Icon
Email Icon
Physician HeadShot

Anca D. Askanase, MD, MPH

Rheumatology (Board Certified, Primary Specialty)
Sjogren's Syndrome
Languages: French, Romanian, Spanish
Office Phone: (212) 305-4308
One of America's Top Doctors


Dr. Anca Dinu Askanase recently joined the CUMC Rheumatology faculty where she is the founder and clinical director of Columbia's new Lupus Center and the Director of Rheumatology Clinical Trials. Dr. Askanase is an internationally renowned clinician, diagnostician and researcher with more than 15 years specializing in complex Systemic Lupus Erythematosus (SLE). Dr. Askanase trained as a rheumatologist at New York University where she remained for more than 15 years on faculty, directing clinical trials, training fellows and residents, and treating challenging cases of SLE at NYU's prestigious Hospitals.

Dr. Askanase's academic career has focused primarily on the care of patients with SLE and other autoimmune diseases.In order to provide better care for patients suffering from these devastating diseases, she embarked on a journey of research and discovery, with the goal of understanding disease outcomes from both the patients' and physicians' perspective while helping to redefine 21st century therapeutic options. It is Dr. Askanase's hope that by helping to establish widely accepted parameters for quantifying the impact of the disease and the response to medications, all doctors will have effective benchmarks and therapeutic options to better treat patients with SLE's often confounding symptoms.

In addition to numerous publications and benchmark clinical trials, Dr. Askanase is a member of the two major international consortia aimed at providing the collaboration between lupus doctors needing to improve outcomes and therapies in Lupus: the SLICC (SLE international Collaborating Clinics) and the LNTN (Lupus Nephritis Trial Network).Dr. Askanase believes that excellent care often involves bringing novel therapies to her patients with Lupus and other autoimmune diseases; thus, she has been involved in every major SLE clinical drug trial and multiple NIH and industry sponsored clinical trials. One of her most rewarding experiences was her involvement as the Site Principal Investigator in the registrational study that led to the FDA approval of Belimumab, the first new Lupus drug in over 50 years. Dr. Askanase also designed and executed the only study looking at a rational approach (based on pharmacogenetics and metabolite measurement) to use Azathioprine in the treatment of Lupus. She is currently evaluating the use of ACTH as a steroid alternative in lupus nephritis. Dr. Askanase is also a proud Columbia Alumnus and still lives in Morningside Heights with her husband and two children.

Area of Expertise

Please contact the doctor's office to verify that your insurance is accepted.

Aetna [EPO, HMO, Medicare Managed Care, NY Signature, NYP Employee Plan, POS, PPO, Signature Administrators, Student Health]

Cigna [EPO, Great West, HMO, POS, PPO]

Empire Blue Cross Blue Shield [EPO, HMO, Medicare Managed Care, POS, PPO]

Local 1199 [Local 1199]

Oxford Health Plans [Freedom, Liberty]


UnitedHealthcare [Columbia University Employee Plan, HMO, Medicare Managed Care, POS, PPO]


MPH, Columbia University, Mailman School of Public Health

1989 Instit De Medicina Si Farmacie Carol Davila

MD, Institute of Medicine and Pharmacy-Carol Davilla (Romania)

2003 Columbia University School of Public Health

Internship: St. Lukes Roosevelt Hospital Center

Residency: St. Lukes Roosevelt Hospital Center

Fellowship: Hospital for Joint Diseases